ID   NKM-1
AC   CVCL_1607
SY   NKM1
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03472796
DR   Cell_Model_Passport; SIDM00576
DR   ChEMBL-Cells; CHEMBL3308212
DR   ChEMBL-Targets; CHEMBL2366133
DR   Cosmic; 908448
DR   Cosmic; 1523824
DR   Cosmic; 2131549
DR   Cosmic; 2306228
DR   Cosmic-CLP; 908448
DR   DepMap; ACH-002290
DR   EGA; EGAS00001000978
DR   GDSC; 908448
DR   GEO; GSM1670279
DR   IARC_TP53; 21586
DR   JCRB; IFO50476
DR   LINCS_LDP; LCL-1073
DR   PharmacoDB; NKM1_1161_2019
DR   PRIDE; PXD030304
DR   Wikidata; Q54930681
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=1699657;
RX   PubMed=1701353;
RX   PubMed=1701357;
RX   PubMed=9737686;
RX   PubMed=9738977;
RX   PubMed=20164919;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Doubling time: 36-48 hours (PubMed=1701353).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=76.96%; East Asian, South=21.17%; South Asian=0.96%; European, North=0.9%; European, South=0.01% (PubMed=30894373).
CC   Derived from sampling site: Peripheral blood.
ST   Source(s): Cosmic-CLP; JCRB
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 11,13
ST   D16S539: 9,12
ST   D5S818: 10,12
ST   D7S820: 10,11
ST   TH01: 6,9
ST   TPOX: 9,11
ST   vWA: 17
DI   NCIt; C9154; Adult acute myeloid leukemia
DI   ORDO; Orphanet_519; Acute myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   33Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 22-09-22; Version: 30
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=1699657;
RA   Towatari M., Ito Y., Morishita Y., Tanimoto M., Kawashima K.,
RA   Morishima Y., Andoh T., Saito H.;
RT   "Enhanced expression of DNA topoisomerase II by recombinant human
RT   granulocyte colony-stimulating factor in human leukemia cells.";
RL   Cancer Res. 50:7198-7202(1990).
//
RX   PubMed=1701353;
RA   Kataoka T., Morishita Y., Ogura M., Morishima Y., Towatari M.,
RA   Kato Y., Inoue H., Saito H.;
RT   "A novel human myeloid leukemia cell line, NKM-1, coexpressing
RT   granulocyte colony-stimulating factor receptors and macrophage
RT   colony-stimulating factor receptors.";
RL   Cancer Res. 50:7703-7709(1990).
//
RX   PubMed=1701357;
RA   Morishita Y., Kataoka T., Towatari M., Ito T., Inoue H., Ogura M.,
RA   Morishima Y., Saito H.;
RT   "Up-regulation of transferrin receptor gene expression by granulocyte
RT   colony-stimulating factor in human myeloid leukemia cells.";
RL   Cancer Res. 50:7955-7961(1990).
//
RX   PubMed=9737686; DOI=10.1038/sj.leu.2401112;
RA   Zhang W., Ohnishi K., Shigeno K., Fujisawa S., Naito K., Nakamura S.,
RA   Takeshita K., Takeshita A., Ohno R.;
RT   "The induction of apoptosis and cell cycle arrest by arsenic trioxide
RT   in lymphoid neoplasms.";
RL   Leukemia 12:1383-1391(1998).
//
RX   PubMed=9738977; DOI=10.1111/j.1349-7006.1998.tb03275.x;
RA   Takizawa J., Suzuki R., Kuroda H., Utsunomiya A., Kagami Y., Joh T.,
RA   Aizawa Y., Ueda R., Seto M.;
RT   "Expression of the TCL1 gene at 14q32 in B-cell malignancies but not
RT   in adult T-cell leukemia.";
RL   Jpn. J. Cancer Res. 89:712-718(1998).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//